INDP Key Statistics, Chart & Performance
The current stock price of INDP is 2.91 USD. In the past month the price increased by 45.5%. In the past year, price decreased by -88.19%.
INDP Latest News, Press Relases and Analysis
INDP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 24.18 | 403.83B | ||
| AMGN | AMGEN INC | 14.97 | 176.25B | ||
| GILD | GILEAD SCIENCES INC | 14.99 | 152.28B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 26.12 | 115.03B | ||
| REGN | REGENERON PHARMACEUTICALS | 17.15 | 81.12B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 779.71 | 52.53B | ||
| INSM | INSMED INC | N/A | 37.12B | ||
| NTRA | NATERA INC | N/A | 31.62B | ||
| BIIB | BIOGEN INC | 10.51 | 25.82B | ||
| UTHR | UNITED THERAPEUTICS CORP | 18.46 | 20.98B | ||
| INCY | INCYTE CORP | 15.38 | 19.39B | ||
| EXAS | EXACT SCIENCES CORP | N/A | 19.27B |
Related stock screener links
About INDP
Company Profile
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
Company Info
INDAPTUS THERAPEUTICS INC
3 Columbus Circle, 15th Floor
New York City NEW YORK US
CEO: Jeffrey A. Meckler
Employees: 7
Phone: 16464272727
INDAPTUS THERAPEUTICS INC / INDP FAQ
Can you describe the business of INDAPTUS THERAPEUTICS INC?
Indaptus Therapeutics, Inc. is a pre-clinical biotechnology company. The company is headquartered in New York City, New York and currently employs 7 full-time employees. The company went IPO on 2012-09-07. The Company’s approach is based on the hypothesis that activation of both innate and adaptive immune cells and pathways and associated anti-tumor and anti-viral immune responses will require a multi-targeted package of immune system-activating signals that can be administered safely intravenously (i.v.). Its technology is composed of single strains of attenuated and killed, non-pathogenic, Gram-negative bacteria producing a multiple Toll-like receptor (TLR), Nucleotide oligomerization domain (NOD)-like receptor (NLR) and Stimulator of interferon genes (STING) agonist Decoy platform. The firm's lead clinical candidate is Decoy20. Its Decoy product candidates have also produced significant single agent activity against chronic hepatitis B virus (HBV) and chronic human immunodeficiency virus (HIV) infections in pre-clinical models.
What is the current price of INDP stock?
The current stock price of INDP is 2.91 USD. The price increased by 6.99% in the last trading session.
What is the dividend status of INDAPTUS THERAPEUTICS INC?
INDP does not pay a dividend.
What is the ChartMill rating of INDAPTUS THERAPEUTICS INC stock?
INDP has a ChartMill Technical rating of 2 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the analyst forecast for INDP stock?
7 analysts have analysed INDP and the average price target is 10.2 USD. This implies a price increase of 250.52% is expected in the next year compared to the current price of 2.91.
What is INDAPTUS THERAPEUTICS INC worth?
INDAPTUS THERAPEUTICS INC (INDP) has a market capitalization of 5.09M USD. This makes INDP a Nano Cap stock.
INDP Technical Analysis
ChartMill assigns a technical rating of 2 / 10 to INDP. When comparing the yearly performance of all stocks, INDP is a bad performer in the overall market: 93.37% of all stocks are doing better.
INDP Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to INDP. INDP scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
INDP Financial Highlights
Over the last trailing twelve months INDP reported a non-GAAP Earnings per Share(EPS) of -31.67. The EPS increased by 34.24% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -246.6% | ||
| ROE | -366.23% | ||
| Debt/Equity | 0 |
INDP Forecast & Estimates
7 analysts have analysed INDP and the average price target is 10.2 USD. This implies a price increase of 250.52% is expected in the next year compared to the current price of 2.91.